Quantcast
Last updated on April 17, 2014 at 15:50 EDT

Latest Androgen Stories

2014-03-27 08:33:33

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/djkgl4/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of Prostate Cancer" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide,...

2013-12-17 23:01:50

Supplement Edge is now offering RPN Havoc and IBE Epistane at big discounts online at http://www.supplementedge.com/. Los Angeles, CA (PRWEB) December 17, 2013 Supplement Edge, a reliable and established online provider of health and wellness products, has added two new exciting products to their line-up: RPN Havoc and IBE Epistane. The supplements contain the latest blends to help provide natural increases in muscle strength and lean muscle gains. Anabolic supplements can be a...

2013-08-14 23:20:12

A New York fertility center CHR receives two new patents that could improve pregnancy chances for women with diminished ovarian reserve. New York, NY (PRWEB) August 14, 2013 Center for Human Reproduction (CHR), a leading fertility research and treatment center in New York City, announced approval of two patent applications regarding the therapeutic benefits and mechanisms of androgen supplementation for pregnancy chances of women with diminished ovarian reserve (DOR). Combined, the two...

2013-03-18 20:42:21

Sanford-Burnham researchers discover that a protein called Siah2 helps prostate cancer cells resist hormone therapy -- ;making it an attractive biomarker and therapeutic target Hormonal therapies can help control advanced prostate cancer for a time. However, for most men, at some point their prostate cancer eventually stops responding to further hormonal treatment. This stage of the disease is called androgen-insensitive or castration-resistant prostate cancer. In a study published March...

2013-02-11 15:53:09

Prostate cancer in younger patients is triggered by a different mechanism than in older men While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50. Scientists at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, in collaboration with several other research teams in Germany, have discovered that such early-onset prostate cancers are triggered by a different mechanism from that which...

2012-12-14 15:12:38

Previously unknown protein function could be a treatment target Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs. The researchers report in the Dec. 14 issue of Science that the molecular...

2012-09-20 16:52:24

The androgen receptor in human cells inhibits fat accumulation, but its activity can be sabotaged by glucocorticoids, steroids that regulate fat deposition and are known drivers of obesity and insulin resistance, said researchers led by those at Baylor College of Medicine (www.bcm.edu) in a report in the journal Chemistry & Biology (https://www.cell.com/chemistry-biology/home). "The project started with a straightforward search for genes or signals specific to human fat cells," said...

2012-07-18 02:22:37

SANTA ROSA, Calif., July 18, 2012 /PRNewswire/ -- Doxorubicin (Dox) is an effective anti-cancer drug, but it's also a very toxic one, causing severe heart and immune damage. The doses needed to impact tumors are not well tolerated by patients; however, researchers may have found an answer through combination therapy. A study published in the journal Cell Biology International has shown that combining Dox with the natural supplement Modified Citrus Pectin (MCP) increases the anti-cancer...

2012-07-18 01:05:17

A small, naturally occurring nucleic acid sequence, called a microRNA, known to regulate a number of different cancers, appears to alter the activity of the androgen receptor, which plays a critical role in prostate cancer. Directly targeting microRNA-125b to block androgen receptor activity represents a novel approach for treating castrate-resistant prostate cancer. This promising new strategy for improving the effectiveness of anti-androgenic and other hormonal therapies is described in an...

2012-04-04 09:26:44

Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels, according to data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. If confirmed, these data mean that levels of hormones, specifically adrenal androgens, may provide physicians with another way to predict the efficacy of therapy in patients with...